• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Stem Cell Extracellular Vesicles Protect Mouse Oocytes From Cyclophosphamide Chemotherapy Damage

by
November 19, 2026
in Health
Reading Time: 3 mins read
0
Stem Cell Extracellular Vesicles Protect Mouse Oocytes From Cyclophosphamide Chemotherapy Damage

Stem Cell Extracellular Vesicles Protect Mouse Oocytes From Cyclophosphamide Chemotherapy Damage

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Cyclophosphamide serves as an alkylating chemotherapeutic agent frequently administered as a primary first-line treatment for hematological tumors in preadolescent female patients. Although clinically effective against malignant diseases, cyclophosphamide is recognized to cause significant cellular damage to developing oocytes. Human amniotic mesenchymal stem cells possess antioxidant and anti-apoptotic properties. Consequently, extracellular vesicles derived from these stem cells were investigated for their antioxidant capacity to alleviate cyclophosphamide-induced oxidative stress and preserve oocyte quality in experimental models.

To examine these protective effects systematically, researchers utilized prepubertal female C57BL/6J mice aged three to six weeks. The in vivo protocol involved administering intraperitoneal injections of cyclophosphamide to the test subjects, while control animals received equivalent intraperitoneal injections of normal saline. After the animals reached sexual maturity, cumulus oocyte complexes were harvested from the female mice and subjected to in vitro maturation and in vitro fertilization to evaluate the direct impact of chemotherapy exposure on oocyte quality.

In an accompanying in vitro model, cumulus oocyte complexes isolated from preadolescent mice were maintained in culture medium supplemented with 4-hydroxycyclophosphamide at a concentration of 1 micromolar. Because 4-hydroxycyclophosphamide represents an active intermediate metabolite of cyclophosphamide, this approach permitted the direct modeling of chemotherapeutic stress under defined laboratory conditions. Investigators subsequently evaluated the specific cytoprotective mechanisms of human amniotic mesenchymal stem cell-derived extracellular vesicles on these chemically injured cells.

The experimental results showed that direct intraperitoneal injection of cyclophosphamide altered reproductive outcomes in the animal model. Specifically, cyclophosphamide administration reduced the total number of viable mouse oocytes retrieved following ovulation induction. Furthermore, cyclophosphamide treatment significantly decreased the mitochondrial membrane potential of in vitro matured oocytes (p < 0.05) while causing a statistically significant elevation in intracellular reactive oxygen species content (p < 0.05).

Direct in vitro exposure to 1 micromolar 4-hydroxycyclophosphamide also induced substantial physiological impairment in the cultured oocytes. The metabolite significantly reduced mitochondrial membrane potential (p < 0.05) and significantly lowered cytoplasmic maturity (p < 0.05). Additionally, treatment with 4-hydroxycyclophosphamide produced a statistically significant increase in intracellular superoxide anion levels (p < 0.05), confirming that cyclophosphamide metabolites trigger severe oxidative stress and compromise cytoplasmic maturation.

Assessment of subsequent embryonic development revealed further chemotherapeutic disruptions. Following cyclophosphamide administration, the embryonic cleavage rate displayed an observable downward trend; however, this reduction did not achieve statistical significance (p = 0.1741). In contrast, the subsequent rate of blastocyst formation from treated oocytes exhibited a statistically significant decrease (p < 0.05), demonstrating that chemotherapeutic exposure impairs downstream developmental competence.

Treatment with human amniotic mesenchymal stem cell-derived extracellular vesicles counteracted these chemotherapeutic injuries across both experimental settings. The extracellular vesicles successfully mitigated intracellular oxidative stress induced either by intraperitoneal cyclophosphamide injection or by in vitro 4-hydroxycyclophosphamide exposure. Importantly, vesicle intervention restored developmental potential, yielding a statistically significant improvement in the blastocyst formation rate of the treated oocytes (p < 0.05).

Molecular analysis confirmed that human amniotic mesenchymal stem cell-derived extracellular vesicles down-regulated the overexpression of stress-associated genes in vitro. Vesicle supplementation significantly reduced the elevated expression levels of KLF4, P53, and P21 caused by cyclophosphamide and 1 micromolar 4-hydroxycyclophosphamide (p < 0.05). The researchers concluded that cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide diminish oocyte quality and embryo development, while stem cell-derived extracellular vesicles preserve both cellular integrity and subsequent developmental viability.

Subject of Research: Human amniotic mesenchymal stem cell-derived extracellular vesicles preserving oocyte quality during cyclophosphamide chemotherapy

Article Title: Human amniotic mesenchymal stem cell-derived extracellular vesicles improve the maturation and developmental potential of oocytes cultured in vitro after cyclophosphamide treatment

Article References: Cheng, L., Feng, C., Qian, J., Wang, J., Ni, M., Guo, S., Wu, H., Yan, Z., Ning, S., Jiang, C., Qin, L., & Ma, X. (2026). Human amniotic mesenchymal stem cell-derived extracellular vesicles improve the maturation and developmental potential of oocytes cultured in vitro after cyclophosphamide treatment. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02345-x

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02345-x

Keywords: cyclophosphamide, 4-hydroxycyclophosphamide, oocytes, in vitro maturation, extracellular vesicles, human amniotic mesenchymal stem cells, mitochondrial membrane potential, reactive oxygen species, superoxide anions, blastocyst formation, cumulus oocyte complexes, KLF4, P53, P21, C57BL/6J mice, chemotherapeutic stress

News Source: Nathaniel Bowman. (November 19, 2026). Stem Cell Extracellular Vesicles Protect Mouse Oocytes From Cyclophosphamide Chemotherapy Damage. Scienmag.

Tags: 4-hydroxycyclophosphamideblastocyst formationC57BL/6J micechemotherapeutic stresscumulus oocyte complexescyclophosphamideextracellular vesicleshuman amniotic mesenchymal stem cellsin vitro maturationKlf4mitochondrial membrane potentialoocytesp21p53reactive oxygen speciessuperoxide anions
Share12Tweet7Share2ShareShareShare1

Related Posts

India Maps Regional Viral Outbreak Priorities to Guide Zonal Pandemic Preparedness

India Maps Regional Viral Outbreak Priorities to Guide Zonal Pandemic Preparedness

November 19, 2026
Mitochondrial-ER Contact Loss Linked to Sarcopenia and Anabolic Resistance, Review Finds

Mitochondrial-ER Contact Loss Linked to Sarcopenia and Anabolic Resistance, Review Finds

November 19, 2026

Systematic Review Details Diagnostic Inequities Faced by Sexual and Gender Minorities

November 19, 2026

Sarcopenia Combined With Visceral Obesity Increases Postoperative Delirium Risk in Older Adults

November 19, 2026

POPULAR NEWS

  • Cyanoacrylate Adhesives Speed Extraoral Skin Closure but Certainty Remains Low

    Cyanoacrylate Adhesives Speed Extraoral Skin Closure but Certainty Remains Low

    29 shares
    Share 12 Tweet 7
  • Mid-size Unmanned Ground Vehicles Face Severe Mobility and Scalability Constraints

    29 shares
    Share 12 Tweet 7
  • Computational Framework Matches Biodegradable Implant Resorption Rates to Bone Healing Timelines

    29 shares
    Share 12 Tweet 7
  • Robotic Exoskeleton Gait Training Earns High Satisfaction Despite Wearability and Cost Challenges

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Review Compares siRNA, miRNA, and CRISPR Platforms for Precision Gene Regulation

India Maps Regional Viral Outbreak Priorities to Guide Zonal Pandemic Preparedness

Review Surveys Waveguide Integration for Two-Dimensional Material Infrared Photodetectors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.